The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

By D. Goff, J. Coyle. American Journal of Psychiatry, 2001

935 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Computational Anatomy of Psychosis (2013, background): “NMDA-Rs play a central role in theories of schizophrenia (Olney and Farber, 1995; Abi-Saab et al., 1998; Goff and Coyle, 2001; Stephan et al., 2006; Corlett et al., 2011).”
Neuregulin 1 and susceptibility to schizophrenia. (2002, background): “It is of interest that some of the atypical antipsychotics (such as clozapine) increase NMDA-receptor expression and directly facilitate glutamatergic transmission (Goff and Coyle 2001).”
Disrupted-in-Schizophrenia-1 (DISC1) regulates spines of the glutamate synapse via Rac1 (2010, background): “2487" language="eng" relation="no"> Disturbances in neuronal connectivity, particularly in glutamatergic synaptic connections, underlie schizophrenia and associated disorder”
Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. (2003, neutral): “It has been postulated that the mesolimbic dopamine abnormality may be a primary neurochemical abnormality (3, 6), a secondary consequence of hypofrontality (1, 156), secondary to a glutamate deficit (33, 157, 158), or secondary to a primary neurodevelopmental disorder (159–161).”